The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Open accessAbstract
Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma concentrations being reached 2-4 h after tablet intake. Oral bioavailability is high (80-100 %) for the 10 mg tablet irrespective of food intake and for the 15 mg and 20 mg tablets when taken with food. Variability in the pharmacokinetic parameters is moderate (coefficient of variation 30-40 %). The pharmacokinetic profile of rivaroxaban is consistent in healthy subjects and across a broad range of different patient populations studied. Elimination of rivaroxaban from plasma occurs with a terminal half-life of 5-9 h in healthy young subjects and 11-13 h in elderly subjects. Rivaroxaban produces a pharmacodynamic effect that is closely correlated with its plasma concentration. The pharmacokinetic and pharmacodynamic relationship for inhibition of Factor Xa activity can be described by an E max model, and prothrombin time prolongation by a linear model. Rivaroxaban does not inhibit cytochrome P450 enzymes or known drug transporter systems and, because rivaroxaban has multiple elimination pathways, it has no clinically relevant interactions with most commonly prescribed medications. Rivaroxaban has been approved for clinical use in several thromboembolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Kakkar, A. K., Brenner, B., Dahl, O. E., Eriksson, B. I., Mouret, P., Muntz, J., Soglian, A. G., Pap, Á. F., Misselwitz, F., & Haas, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60880-6 · Cited by 1,070
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Mega, J., Braunwald, E., Mohanavelu, S., Burton, P., Poulter, R., Misselwitz, F., Hricak, V, Barnathan, E., Bordes, P., Witkowski, A., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60738-8 · Cited by 688
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Self-citationKubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Self-citationFox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr342 · Cited by 608 · cited 1×
“Subgroup analyses of data from the ROCKET AF study demonstrated that the clinical outcomes were consistent between patients receiving rivaroxaban 20 mg once daily (CLCR C50 mL/ min) and those receiving 15 mg once daily (CLCR 30–49 mL/min) [9, 53].”
MethodRivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Cohen, A. T., Spiro, T. E., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1111096 · Cited by 607
PERZBORN, E., STRASSBURGER, J., WILMEN, A., POHLMANN, J., ROEHRIG, S., SCHLEMMER, K.-H., & STRAUB, A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01166.x · Cited by 590
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0176 · Cited by 449
Roehrig, S., Straub, A., Pohlmann, J., Lampe, T., Pernerstorfer, J., Schlemmer, K.-H., Reinemer, P., & Perzborn, E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050101d · Cited by 436
Kubitza, D., Becka, M., Mueck, W., Halabi, A., Maatouk, H., Klause, N., Lufft, V., Wand, D. D., Philipp, T., & Bruck, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03753.x · Cited by 432
Self-citationMueck, W., Kubitza, D., & Becka, M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12075 · Cited by 371
Self-citationWang, Z., Frost, C., Shenker, A., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0328 · Cited by 356
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006296058 · Cited by 334
Self-citationMueck, W., Lensing, A. W. A., Agnelli, G., Decousus, H., Prandoni, P., & Misselwitz, F. (2011) · Clinical Pharmacokinetics · doi:10.2165/11595320-000000000-00000 · Cited by 327
Self-citationThe discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., & Misselwitz, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3185 · Cited by 297
Self-citationBorris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Muelhofer, E., Misselwitz, F., Eriksson, B. I., & Mueck, W. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-12-0714 · Cited by 273
Self-citationKubitza, D., Becka, M., Roth, A., & Mueck, W. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802361499 · Cited by 268
Self-citationUsing the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Stangier, J., & Feuring, M. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834f1b0c · Cited by 265
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006286904 · Cited by 254
Self-citationMueck, W., Eriksson, B. I., Bauer, K. A., Borris, L., Dahl, O. E., Fisher, W. D., Gent, M., Haas, S., Huisman, M. V., Kakkar, A. K., et al. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847030-00006 · Cited by 243
Self-citationContant, G., Spiro, T., Perzborn, E., Guinet, C., Gourmelin, Y., Flem, L., Rohde, G., Martinoli, J., Samama, M., & Laboratories, F. T. R. A.-F. X. C. A. F. T. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-06-0391 · Cited by 232
The effect of food on the absorption and pharmacokinetics of rivaroxaban
Stampfuss, J., Kubitza, D., Becka, M., & Mueck, W. (2013) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201812 · Cited by 216
Self-citationIn Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Gnoth, M. J., Buetehorn, U., Muenster, U., Schwarz, T., & Sandmann, S. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180240 · Cited by 216
Kubitza, D., Roth, A., Becka, M., Alatrach, A., Halabi, A., Hinrichsen, H., & Mueck, W. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12054 · Cited by 205
Self-citationLevi, M., Moore, K. T., Castillejos, C. F., Kubitza, D., Berkowitz, S. D., Goldhaber, S. Z., Raghoebar, M., Patel, M. R., Weitz, J. I., & Levy, J. H. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12599 · Cited by 197
Self-citationSamama, M. M. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2010.09.008 · Cited by 163
Nunnelee, J. D. (2011) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2011.03.002 · Cited by 161
Weitz, J. I., & Bates, S. M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01374.x · Cited by 161
Assays for Measuring Rivaroxaban: Their Suitability and Limitations
Lindhoff-Last, E., Samama, M. M., Ortel, T. L., Weitz, J. I., & Spiro, T. E. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181f2f264 · Cited by 159
GEROTZIAFAS, G. T., ELALAMY, I., DEPASSE, F., PERZBORN, E., & SAMAMA, M. M. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02429.x · Cited by 159
Kubitza, D., Becka, M., Mueck, W., & Zuehlsdorf, M. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02776.x · Cited by 158
Self-citationGraff, J., von Hentig, N., Misselwitz, F., Kubitza, D., Becka, M., Breddin, H., & Harder, S. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007302952 · Cited by 139
Self-citationRohde, G. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.07.015 · Cited by 138
Decrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin
Härtter, S., Koenen‐Bergmann, M., Sharma, A., Nehmiz, G., Lemke, U., Timmer, W., & Reilly, P. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04218.x · Cited by 120
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.5 · Cited by 116
Self-citationTanigawa, T., Kaneko, M., Hashizume, K., Kajikawa, M., Ueda, H., Tajiri, M., Paolini, J. F., & Mueck, W. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-034 · Cited by 114
Self-citationPharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs
Weinz, C., Buetehorn, U., Daehler, H.-P., Kohlsdorfer, C., Pleiß, U., Sandmann, S., Schlemmer, K., Schwarz, T., & Steinke, W. (2005) · Xenobiotica · doi:10.1080/00498250500250493 · Cited by 100
Rohde, G., Stratmann, G., Hesse, C., Herth, N., Schwers, S., Perzborn, E., Lindhoff‐Last, E., & Mani, H. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-12-0832 · Cited by 98
Zhao, X., Sun, P., Zhou, Y., Liu, Y., Zhang, H., Mueck, W., Kubitza, D., Bauer, R., Zhang, H., & Cui, Y. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03390.x · Cited by 73
Self-citationJiang, J., Hu, Y., Zhang, J., Yang, J., Mueck, W., Kubitza, D., Bauer, R., Meng, L., & Hu, P. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0196 · Cited by 71
Self-citationZhang, D., Frost, C. E., He, K., Rodrigues, A. D., Wang, X., Wang, L., Goosen, T. C., & Humphreys, W. G. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050575 · Cited by 64
Moore, K. T., Plotnikov, A. N., Thyssen, A., Vaccaro, N. M., Ariyawansa, J., & Burton, P. B. J. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31822f6c2b · Cited by 59
Xu, X. S., Moore, K. T., Burton, P. B. J., Stuyckens, K., Mueck, W., Rossenu, S., Plotnikov, A. N., Gibson, C. M., & Vermeulen, A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04181.x · Cited by 56
Self-citationKubitza, D., Mueck, W., & Becka, M. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00006 · Cited by 53
Self-citationKubitza, D., Becka, M., Roth, A., & Mueck, W. (2012) · Journal of International Medical Research · doi:10.1177/030006051204000508 · Cited by 53
Self-citationLaboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays
Lindhoff‐Last, E., Ansell, J., Spiro, T. E., & Samama, M. M. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.801274 · Cited by 53
Biology of Renal Aging in Humans
Clark, B. A. (2000) · Advances in Renal Replacement Therapy · doi:10.1016/s1073-4449(00)70002-1 · Cited by 44
Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
Burghaus, R., Coboeken, K., Gaub, T., Kuepfer, L., Sensse, A., Siegmund, H., Weiß, W. W., Mueck, W., & Lippert, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017626 · Cited by 41
Self-citationKubitza, D., Becka, M., Mück, W. M., & Schwers, S. (2012) · Pharmaceuticals · doi:10.3390/ph5030279 · Cited by 39
Self-citationGheorghiade, M., Thyssen, A., Zolynas, R., Nadar, V., Greenberg, B., Mehra, M. R., Sun, X., Tian, H., Plotnikov, A. N., & Burton, P. B. J. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.08.027 · Cited by 32
Kubitza, D., Becka, M., Schwers, S., & Voith, B. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.26 · Cited by 30
Self-citation
Cited by
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Andrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Gosselin, R., Adcock, D., Bates, S., Douxfils, J., Favaloro, E., Gouin-Thibault, I., Guillermo, C., Kawai, Y., Lindhoff-Last, E., & Kitchen, S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1627480 · Cited by 392
Metadata
- Authors
- Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M.
- Venue
- Clinical Pharmacokinetics
- Published
- 2013-09-03
- Volume
- 53
- Issue
- 1
- Pages
- 1-16
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2017582897
- Cited by
- 612
- References
- 63
- FWCI
- 22.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.